(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 21.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Tarsus Pharmaceuticals's revenue in 2026 is $682,203,000.On average, 12 Wall Street analysts forecast TARS's revenue for 2026 to be $37,058,052,883, with the lowest TARS revenue forecast at $34,231,858,643, and the highest TARS revenue forecast at $38,543,629,165. On average, 12 Wall Street analysts forecast TARS's revenue for 2027 to be $48,404,739,565, with the lowest TARS revenue forecast at $43,970,691,274, and the highest TARS revenue forecast at $59,413,190,160.
In 2028, TARS is forecast to generate $59,758,329,024 in revenue, with the lowest revenue forecast at $51,918,746,256 and the highest revenue forecast at $71,542,355,952.